JP2023515941A5 - - Google Patents
Info
- Publication number
- JP2023515941A5 JP2023515941A5 JP2022550156A JP2022550156A JP2023515941A5 JP 2023515941 A5 JP2023515941 A5 JP 2023515941A5 JP 2022550156 A JP2022550156 A JP 2022550156A JP 2022550156 A JP2022550156 A JP 2022550156A JP 2023515941 A5 JP2023515941 A5 JP 2023515941A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- bispecific antigen
- chain complementarity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062982989P | 2020-02-28 | 2020-02-28 | |
| US62/982,989 | 2020-02-28 | ||
| PCT/US2021/020074 WO2021174113A1 (en) | 2020-02-28 | 2021-02-26 | Bispecific antigen binding molecules that bind her2, and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023515941A JP2023515941A (ja) | 2023-04-17 |
| JP2023515941A5 true JP2023515941A5 (OSRAM) | 2024-03-01 |
| JP7695260B2 JP7695260B2 (ja) | 2025-06-18 |
Family
ID=75108909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550156A Active JP7695260B2 (ja) | 2020-02-28 | 2021-02-26 | Ｈｅｒ２に結合する二重特異性抗原結合分子およびその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11958910B2 (OSRAM) |
| EP (1) | EP4110472A1 (OSRAM) |
| JP (1) | JP7695260B2 (OSRAM) |
| KR (1) | KR20220148200A (OSRAM) |
| CN (1) | CN115175737A (OSRAM) |
| AU (1) | AU2021228225A1 (OSRAM) |
| CA (1) | CA3166619A1 (OSRAM) |
| IL (1) | IL295312A (OSRAM) |
| MX (1) | MX2022010599A (OSRAM) |
| WO (1) | WO2021174113A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118027137A (zh) | 2018-12-21 | 2024-05-14 | 里珍纳龙药品有限公司 | 微管溶素及蛋白质-微管溶素偶联物 |
| IL295312A (en) | 2020-02-28 | 2022-10-01 | Regeneron Pharma | Bispecific antigen binding molecules that bind her2, and methods of use thereof |
| EP4171653A2 (en) * | 2020-06-24 | 2023-05-03 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
| US12605459B2 (en) | 2020-07-13 | 2026-04-21 | Regeneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
| US20240307551A1 (en) * | 2021-07-05 | 2024-09-19 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | Antibody-drug conjugate and application thereof |
| WO2023098691A1 (zh) * | 2021-12-01 | 2023-06-08 | 上海生物制品研究所有限责任公司 | 抗体药物偶联物及其用途 |
| CN118829449A (zh) * | 2022-01-12 | 2024-10-22 | 瑞泽恩制药公司 | 与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途 |
| JP2025528087A (ja) * | 2022-08-05 | 2025-08-26 | チマゲン・バイオサイエンシズ，リミテッド | 二量体化可能な腫瘍抗原及び免疫刺激抗原を標的とする多重特異性抗体 |
| CN120752059A (zh) * | 2022-12-21 | 2025-10-03 | 瑞泽恩制药公司 | 用于adc缀合的拓扑异构酶i抑制剂的前药及其使用方法 |
| US20250255980A1 (en) * | 2024-02-12 | 2025-08-14 | Mbrace Therapeutics, Inc. | Antibody-Drug Conjugates Against the Glucose-regulating Protein 78 (GRP78) |
| WO2025199666A1 (en) * | 2024-03-25 | 2025-10-02 | Canwell Biotech Limited | Multivalent linkers for high loading antibody-drug conjugates, and compositions and methods thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US585592A (en) | 1897-06-29 | Reversing-valve | ||
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| NZ587107A (en) | 2006-06-02 | 2012-05-25 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| ES2731432T3 (es) | 2007-05-23 | 2019-11-15 | Ventana Med Syst Inc | Transportadores poliméricos para inmunohistoquímica e hibridación in situ |
| RU2487877C2 (ru) | 2008-04-30 | 2013-07-20 | Иммьюноджен, Инк. | Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры) |
| WO2010010324A1 (en) | 2008-07-21 | 2010-01-28 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| WO2011018613A1 (en) | 2009-08-10 | 2011-02-17 | Ucl Business Plc | Functionalisation of solid substrates |
| WO2011130598A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| WO2012005982A2 (en) | 2010-07-06 | 2012-01-12 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Reporter for rna polymerase ii termination |
| CN103328505B (zh) | 2010-10-29 | 2015-12-02 | 伊缪诺金公司 | 非拮抗性egfr结合分子及其免疫偶联物 |
| EP2714685B1 (en) | 2011-05-27 | 2016-10-19 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| SG11201401021TA (en) | 2011-10-14 | 2014-08-28 | Spirogen Sarl | Pyrrolobenzodiazepines |
| US9102704B2 (en) | 2011-10-14 | 2015-08-11 | Spirogen Sarl | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
| MX358757B (es) | 2011-10-14 | 2018-09-03 | Seattle Genetics Inc | Pirrolobenzodiazepinas y conjugados dirigidos. |
| US9526798B2 (en) | 2011-10-14 | 2016-12-27 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| AU2012348017A1 (en) | 2011-12-05 | 2014-07-03 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates and related compounds, compositions, and methods |
| ES2659270T5 (en) | 2012-10-23 | 2026-02-11 | Synaffix Bv | Modified antibody, antibody-conjugate and process for the preparation thereof |
| JP6400595B2 (ja) | 2012-12-21 | 2018-10-03 | グレンマーク ファーマシューティカルズ， エセ．アー． | 抗ｈｅｒ２抗体製剤 |
| EP3964237B1 (en) | 2013-03-15 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
| KR102252925B1 (ko) | 2013-08-26 | 2021-05-18 | 리제너론 파마슈티칼스 인코포레이티드 | 마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도 |
| CA2925677A1 (en) | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | Bispecific her2 antibodies and methods of use |
| SG11201608192SA (en) | 2014-04-11 | 2016-10-28 | Medimmune Llc | Bispecific her2 antibodies |
| KR20240142591A (ko) | 2015-03-27 | 2024-09-30 | 리제너론 파아마슈티컬스, 인크. | 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법 |
| CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
| MY198605A (en) | 2016-01-25 | 2023-09-08 | Regeneron Pharma | Maytansinoid derivatives conjugates thereof, and methods of use |
| WO2018044540A1 (en) | 2016-08-31 | 2018-03-08 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for detecting protein trafficking |
| KR20250114431A (ko) | 2016-11-08 | 2025-07-29 | 리제너론 파마슈티칼스 인코포레이티드 | 스테로이드 및 이의 단백질-접합체 |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| WO2018182420A1 (en) * | 2017-03-31 | 2018-10-04 | Merus N.V. | Antibodies for the treatment of erbb-2/erbb-3 positive tumors |
| US11780925B2 (en) * | 2017-03-31 | 2023-10-10 | Merus N.V. | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene |
| CN112074538B (zh) * | 2018-04-30 | 2024-10-18 | 瑞泽恩制药公司 | 结合her2和/或aplp2的抗体和双特异性抗原结合分子、其缀合物和用途 |
| IL295312A (en) | 2020-02-28 | 2022-10-01 | Regeneron Pharma | Bispecific antigen binding molecules that bind her2, and methods of use thereof |
-
2021
- 2021-02-26 IL IL295312A patent/IL295312A/en unknown
- 2021-02-26 KR KR1020227031324A patent/KR20220148200A/ko active Pending
- 2021-02-26 US US17/187,511 patent/US11958910B2/en active Active
- 2021-02-26 CN CN202180017266.5A patent/CN115175737A/zh active Pending
- 2021-02-26 WO PCT/US2021/020074 patent/WO2021174113A1/en not_active Ceased
- 2021-02-26 JP JP2022550156A patent/JP7695260B2/ja active Active
- 2021-02-26 EP EP21713314.9A patent/EP4110472A1/en active Pending
- 2021-02-26 AU AU2021228225A patent/AU2021228225A1/en active Pending
- 2021-02-26 MX MX2022010599A patent/MX2022010599A/es unknown
- 2021-02-26 CA CA3166619A patent/CA3166619A1/en active Pending
-
2024
- 2024-03-08 US US18/600,481 patent/US12583939B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023547323A5 (OSRAM) | ||
| JP2024059609A5 (OSRAM) | ||
| CN112646031A (zh) | 抗4-1bb纳米抗体及其用途 | |
| EP3880712A1 (en) | MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF | |
| KR102949500B1 (ko) | 접합을 위한 폴리펩티드 복합체 및 이의 용도 | |
| JP2019536740A5 (OSRAM) | ||
| CN111712520A (zh) | 磷脂酰肌醇聚糖3抗体及其偶联物 | |
| JP2015520758A (ja) | Ｃｄ３３抗体及び癌を処置するためのその使用 | |
| JP2012522513A5 (OSRAM) | ||
| JP2021523100A5 (OSRAM) | ||
| JP7264831B2 (ja) | 抗ｇｌｏｂｏ ｈ抗体を含有する抗体－薬物コンジュゲートおよびその使用 | |
| JP2024525624A (ja) | 抗体薬物コンジュゲート及びその使用 | |
| JP2025038088A5 (OSRAM) | ||
| EP3200822A1 (en) | Binding molecules, especially antibodies, binding to l1cam (cd171) | |
| JP2022523360A5 (OSRAM) | ||
| US20230312742A1 (en) | CD38 antibodies for the treatment of human diseases | |
| JP2024533457A5 (OSRAM) | ||
| JP2024517760A (ja) | 抗５ｔ４抗体及びその使用 | |
| TW202511297A (zh) | 一種抗gpc3抗體或抗原結合片段及其用途 | |
| TW202432185A (zh) | 配體－細胞毒性藥物綴合物及其藥物用途 | |
| JP2024540536A5 (OSRAM) | ||
| JP2024527235A5 (OSRAM) | ||
| US20240417457A1 (en) | Antibodies directed against alpha-folate receptor | |
| WO2025233679A1 (en) | Compositions and methods related to a combination therapy of sting agonists and antibody drug conjugates | |
| CN120829509A (zh) | 抗ror1抗体、其免疫缀合物及其应用 |